📰 Demonstrate Efficacy News

Demonstrate Efficacy News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Demonstrate Efficacy. Real-time updates on events, politics, business and more.

New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting

May 4, 2024

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in...

United States Traci Mccarty Hank Fuchs Biomarin Rareconnections Andrew Dauber Andrew Villani

Source: prnewswire.com

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

January 3, 2024

03.01.2024 - –Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved for Key Secondary Endpoints of Change From Baseline in Both FACIT-Fatigue Score and Hemoglobin ... Seite 1

United Kingdom Ali Taher Sarah Gheuens American University Of Beirut Medical Center Agios Pharmaceuticals Inc Naefk Basile Cancer Institute

Source: wallstreet-online.de

Ocuphire Announces Positive Topline Results from LYNX-1

May 19, 2022

Met FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo ...

Corey Davis Ocuphire Pharma Mina Sooch Ocuphire Pharma Inc Primary Endpoint More Nyxol Subjects Gaining

Source: globenewswire.com

Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

May 19, 2022

Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances - read this article along with other careers information, tips and advice on BioSpace

Corey Davis Ocuphire Pharma Mina Sooch Ocuphire Pharma Inc Primary Endpoint More Nyxol Subjects Gaining

Source: biospace.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation